drugset / Trial / NCT04996056

An Open-Label, Randomized Pilot Study Comparing the Safety of a Single Dose of TNX-1300 to Usual Care (UC) Alone for the Treatment of Signs and Symptoms of Acute Cocaine Intoxication in Male Emergency Department (ED) Subjects

NCT04996056 ↗

Phase 2 Withdrawn Tonix Pharmaceuticals, Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

An Open-Label, Randomized Pilot Study Comparing the Safety of a Single Dose of TNX-1300 to Usual Care (UC) Alone for the Treatment of Signs and Symptoms of Acute Cocaine Intoxication in Male Emergency Department (ED) Subjects

Timeline

Start
2021-09-03
Primary completion
2022-06-16
Completion
2022-06-16

Outcome

Outcome not reported

Stopped (Enrollment): “Not able to recruit qualified participants”

Drugs

EvaluationDrugModalityDoseRoute
Subject TNX-1300 Unknown 200 mg Intravenous

Indications